Restoring immune balance. Transforming lives.

We innovate around the complexities of the immune system to treat the cause of autoimmune disease and not merely the symptoms.

;

About

Everything we do revolves around the immune system.

LAPIX is a clinical-stage biopharmaceutical company dedicated to pioneering innovative and first-in-class treatments for people diagnosed with autoimmune diseases. We take a patient-centric approach by developing novel, orally administered, immune tolerance restoration therapies that are non-immunosuppressive. We believe there is a better, gentler way for treating patients with autoimmune diseases.

Our pursuit of restoring the body’s natural immune tolerance pathway reflects our passion to transform lives through the development of progressive and patient-centric therapies for people suffering from autoimmune diseases with dysregulated Tregs such as Multiple Sclerosis, Rheumatoid Arthritis, Crohn’s Disease, Ulcerative Colitis, and many others.

Our antigen-agnostic immune tolerance restoration approach centered on developing TIM (T-cell immunoglobulin and mucin domain) agonists, combined with our in-depth knowledge of immunology and immune tolerance are the keys to propelling us forward and discovering new ways to restore immune balance.

LAPIX’s therapeutics are meticulously developed to offer safe, efficacious, and patient-focused solutions for addressing a broad spectrum of autoimmune conditions. Our vision is to transform how the medical field currently treats patients with immune-related diseases, and we are deeply committed to helping as many patients as possible.

Inspired to make a difference for patients.

Our vision of changing the way autoimmune diseases are treated necessitates groundbreaking ways of thinking. Our antigen-agnostic, orally administered approach to tolerance induction unleashes the power of immune tolerance by addressing the root cause of autoimmune disease. In doing so, we are enabling a treatment paradigm that breaks free from the shackles of yesteryear immune tolerance technology that has held back the field.”

Anas Fathallah, Ph.D.

Chief Executive Officer and Co-Founder

Our goal is to treat the sources of autoimmune disorders, and we do that by rehabilitating the immune system to its natural balance without the side effects of immune suppression. We are pioneering these treatments because we believe that patients, rightfully, deserve therapeutic choices that prioritize safety, efficacy, and tolerability while safeguarding the overall quality of life of patients.”

Abdulraouf Ramadan, Ph.D.

Head of Immunology

We are at the precipice of unlocking the full potential of TIM receptors and transforming the approach that scientific and medical communities utilize to treat auto-immune diseases.”

Nimita Dave, Ph.D.

Clinical Pharmacology, Drug Metabolism and Pharmacokinetics

Approach

We are unlocking the TIM pathway to explore new treatment options for autoimmune diseases.

By challenging the conventional treatment approach of immune system suppression, and shifting it to our novel, immune tolerance approach, we are discovering new possibilities for patients diagnosed with autoimmune diseases.

Our methodology for treating autoimmune disease through the TIM pathway relies on engaging the TIM receptors (TIM-3, TIM-4) with high-potency induction in an antigen-agnostic manner. This first-of-its-kind solution will replace existing treatments for autoimmune disease. Instead of suppressing the immune system, our therapies reestablish immune balance by restoring Treg and Breg populations to regulate pathogenic T cells.

TIM is exclusively expressed on immune cells and represents the body’s inherent tolerance pathway. Our unique and potent molecules activation of TIM restores immune equilibrium and reduces the harmful effects of renegade immune cells. Our therapies restore Tregs and Bregs (which are typically downregulated in autoimmune disease), while also downregulating pathogenic TH17 (which is typically upregulated by autoimmune disease).

TIM Pathway

The TIM (T-cell immunoglobulin and mucin domain) pathway is the linchpin in immune regulation and tolerance.

The TIM pathway is a complex network of interactions involving TIM family proteins. We believe that it is the starting point for identifying the root cause — and potential cure — of immune-related diseases. These proteins are vital to regulating immune tolerance, T cell responses, inflammation and various immune-related disorders.

The TIM pathway was discovered in the early 2000s and validated by vast research over the last 20 years, and we concentrate on the Tim family of receptors, specifically TIM-3 and TIM-4, because of their central and influential role in immune regulation. The body’s ability to effectively engage TIM is lost during chronic inflammation and can lead to loss of tolerance. The end result can be the development or exacerbation of autoimmune diseases, causing the immune system to mistakenly attack and damage itself.

Our therapeutics are orders of magnitude more potent than TIM’s endogenous ligands and can effectively engage and activate TIM, even under inflammatory conditions. Our data shows that by activating TIM-3 and TIM-4 receptors to restore immune balance, we can treat autoimmune diseases without impacting the immune system’s other functionality, and without inducing neutropenia and lymphocytopenia.

Pipeline

From discovery to clinic, we are advancing a robust pipeline while relentlessly driving forward early-stage initiatives.

Tolerance Induction

Program

Indication

Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3

LPX-TI641

A clinical stage, first-in-class treatment for autoimmune diseases, LPXTI-641 upregulates Tregs and Bregs while downregulating Th17 in an antigen agnostic manner.

Neuro-Autoimmune

Multiple sclerosis (MS)
Neuromyelitis optica (NMO)
MOG-AD (MOGAD)

Rheumatoid Arthritis (RA)

LPX-TIGI

A preclinical asset designed to be gut-restricted for UC and Crohns disease, LPX-TIGI also downregulates TH17 while upregulating Bregs and Tregs. The LPX-TIGI platform will also be utilized for food allergy treatment such as peanut allergy and celiac disease.

Inflammatory Bowel Disease (IBD)

Crohn’s Disease
Ulcerative Colitis

Food Allergy

The co-presentation of foreign antigens with our Tim3/4 agonist allows us to utilize the immune system’s self-tolerance capability to treat non-self-antigen complications, including peanut allergy and celiac disease.

Peanut Allergy Gluten Allergy

Immuno-Oncology

Program

Indication

Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3

LPX-IO

Our approach of antagonizing Tim3/4 receptors challenges the immune-inhibitory effect of tumors. Our Tim3/4 antagonists restore the CD8 T cell functionality by rescuing its capacity to produce cytolytic molecules, and controlling multi-checkpoint expression such as PD-1, KLRG1, CLTA4 and Tim3, which are typically over-expressed due to cancer.

Melanoma AML

Tolerance Induction

LPX-TI641

A clinical stage, first-in-class treatment for autoimmune diseases, LPXTI-641 upregulates Tregs and Bregs while downregulating Th17 in an antigen agnostic manner.

Indication

Neuro-Autoimmune

Multiple sclerosis (MS)
Neuromyelitis optica (NMO)
MOG-AD (MOGAD)

Progress

Phase 1

Indication

Rheumatoid Arthritis (RA)

Progress

Pre-clinical

LPX-TIGI

A preclinical asset designed to be gut-restricted for UC and Crohns disease, LPX-TIGI also downregulates TH17 while upregulating Bregs and Tregs. The LPX-TIGI platform will also be utilized for food allergy treatment such as peanut allergy and celiac disease.

Indication

Inflammatory Bowel Disease (IBD)

Crohn’s Disease
Ulcerative Colitis

Progress

Pre-clinical

Food Allergy

The co-presentation of foreign antigens with our Tim3/4 agonist allows us to utilize the immune system’s self-tolerance capability to treat non-self-antigen complications, including peanut allergy and celiac disease.

Indication

Peanut Allergy

Progress

Discovery

Indication

Gluten Allergy

Progress

Discovery

Immuno-Oncology

LPX-IO

Our approach of antagonizing Tim3/4 receptors challenges the immune-inhibitory effect of tumors. Our Tim3/4 antagonists restore the CD8 T cell functionality by rescuing its capacity to produce cytolytic molecules, and controlling multi-checkpoint expression such as PD-1, KLRG1, CLTA4 and Tim3, which are typically over-expressed due to cancer.

Indication

Melanoma

Progress

Pre-clinical

Indication

AML

Progress

Pre-clinical

News